Use of a PARP inhibitor in maintenance therapy of ovarian cancer
The use of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2,4(1H,3H)-dione as a PARP inhibitor in ovarian cancer maintenance therapy, with dose adjustment to manage toxicities, enhances progression-free survival and reduces disease progression.
WO2025061057A1 Publication Date: 2025-03-27IMPACT THERAPEUTICS (SHANGHAI) INC
3 Cites 18 Cited by
Patent Information
- Application Number
- PCT/CN2024/119509
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-19
- Filing Date
- 2024-09-18
- Publication Date
- 2025-03-27
AI Technical Summary
Technical Problem
Current maintenance therapies for ovarian cancer often result in high incidence and severity of hematological and non-hematological toxicities, leading to permanent discontinuation of treatment and reduced progression-free survival.
Method used
The use of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2,4(1H,3H)-dione, a PARP inhibitor, in a maintenance therapy regimen with dose adjustment to reduce toxicities and improve tolerance, while maintaining therapeutic efficacy.
Benefits of technology
The described regimen effectively reduces the incidence and severity of toxicities, improves patient tolerance, and maintains good drug efficacy, significantly improving progression-free survival and reducing disease progression.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided is the use of a PARP inhibitor in the treatment of a cancer, and in particular to the use of a PARP inhibitor in the maintenance therapy of ovarian cancer. More specifically, provided is a maintenance therapy for a patient with ovarian cancer, which includes administering an effective amount of 5-fluoro-1- (4-fluoro-3- (4- (pyrimidin-2-yl)piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H, 3H) -dione, a hydrate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing 5-fluoro-1- (4-fluoro-3- (4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H, 3H) -dione, the hydrate or the pharmaceutically acceptable salt thereof or a medicament containing the pharmaceutical composition to a patient with ovarian cancer who have received a first-line platinum-containing therapeutic regimen and achieved complete response or partial response.
Need to check novelty before this filing date? Find Prior Art